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INTRODUCTION
Chronic renal failure (CRF) is associated with increased risks 
for stroke and cardiovascular disease.1,2 Thromboembolism is 
one of the major pathologic mechanisms of stroke and car-
diovascular disease,3 and is more frequently noted in patients 
with CRF than in those with normal kidney function.4,5 Several 
abnormalities in hemostasis and coagulation have been sug-
gested in patients with CRF, which induces the activation of 
the renin-angiotensin-aldosterone system. This activation can 
increase the plasma levels of fibrinogen, D-dimer, and plas-
minogen activator inhibitor, which inhibits the activation of 
the fibrinolytic system.6 Patients with CRF show impaired re-
lease of endogenous tissue plasminogen activator from the 
endothelium.7 Moreover, CRF is associated with increased 
platelet aggregation and von Willebrand factor activity.8 These 
features in CRF may result in prothrombotic conditions. On 
the contrary, as CRF advances, the risk of bleeding increases 
in association with platelet dysfunction.9
An appropriate animal model is indispensable to the study 
of CRF. Compared with other animal models for CRF, such as 
ureter occlusion,10 radiation injury,11 or drug-induced CRF,12 
the 5/6 ablation/infarction model has several advantages be-
cause it is very similar to actual glomerular disease in terms of 
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Purpose: Abnormalities in hemostasis and coagulation have been suggested in chronic renal failure (CRF). In this study, we com-
pared processes of thrombus formation between rats with CRF and those with normal kidney function. 
Materials and Methods: CRF was induced by 5/6 ablation/infarction of the kidneys in Sprague-Dawley rats, and surviving rats af-
ter 4 weeks were used. Ferric chloride (FeCl3)-induced thrombosis in the carotid artery was induced to assess thrombus forma-
tion. Whole blood clot formation was evaluated using rotational thromboelastometry (ROTEM). Platelet aggregation was as-
sessed with impedance platelet aggregometry. 
Results: FeCl3-induced thrombus formation was initiated faster in the CRF group than in the control group (13.2±1.1 sec vs. 
17.8±1.0 sec, p=0.027). On histological examination, the maximal diameters of thrombi were larger in the CRF group than in the con-
trol group (394.2±201.1 μm vs. 114.0±145.1 μm, p=0.039). In extrinsic pathway ROTEM, the CRF group showed faster clot initiation 
(clotting time, 59.0±7.3 sec vs. 72.8±5.0 sec, p=0.032) and increased clot growth kinetics (α angle, 84.8±0.2° vs. 82.0±0.6°, p=0.008), 
compared to the control group. Maximal platelet aggregation rate was higher in the CRF group than in the control group 
(58.2±0.2% vs. 44.6±1.2%, p=0.006). 
Conclusion: Our study demonstrated that thrombogenicity is increased in rats with CRF. An activated extrinsic coagulation path-
way may play an important role in increasing thrombogenicity in CRF.
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proteinuria, decreased renal function, and secondary hyper-
tension. However, the surgical procedure is relatively difficult.13 
Although several abnormalities in hemostasis have been sug-
gested in patients with CRF, few studies have examined the 
thrombotic responses to external stimuli in an animal model 
of CRF. 
The prothrombotic state in CRF may result in alterations in 
thrombus formation in pathologic conditions. In this study, we 
compared processes of thrombus formation between rats with 
CRF and those with normal kidney function using the ferric 
chloride (FeCl3)-induced carotid thrombosis model, rotational 
thromboelastometry (ROTEM), and impedance platelet ag-
gregometry (IPA).
MATERIALS AND METHODS
Ethics, animals, and surgical procedures
This study was approved by the Ewha Womans University In-
stitutional Animal Care and Use Committee (ESM 14-0282). All 
procedures performed in studies involving animals were in ac-
cordance with the ethical standards of the institution set in place 
during the time at which the studies were conducted. Eight-
week-old male Sprague-Dawley rats weighing 200−250 g were 
used in all experiments. All rats were maintained in a temper-
ature-controlled room with alternating 12:12-h light-dark cy-
cles, and had free access to water and food throughout the ex-
periments.14 To produce the CRF rat model, all animals were 
anesthetized with 5% isoflurane in a mixture of 30% O2 and 70% 
N2O.15 During the operation, the body temperature of rats was 
monitored continuously with a rectal probe, and maintained 
at 37.0±0.2°C by using a heating pad (Harvard Apparatus, Hol-
liston, MA, USA) and a homeothermic blanket (Harvard Ap-
paratus).15 
In a previous study, the histopathologic findings of CRF 
were confirmed at 2 weeks after 5/6 nephrectomy in remnant 
kidneys of mice.16 Based on this previous study, we performed 
experiments at 4 weeks after 5/6 ablation/infarction of rat kid-
neys. For inducing CRF, a 5/6 ablation/infarction model was 
produced.17 Briefly, after the abdomen was opened through a 
midline incision, the right kidney was removed, and two of 
the three branches of the left renal artery were ligated to induce 
renal infarction in approximately two-thirds of the left kidney.17 
For the control group, a sham operation was performed by means 
of gentle manipulation of the renal pedicles without renal artery 
occlusion or removal of the renal mass. After recovering from 
anesthesia, the rats were returned to their original shelters, which 
were kept warm during 24 hr.18 For this experiment, rats that 
survived until 4 weeks after the induction of CRF were used.
FeCl3-induced common carotid artery thrombosis
At 4 weeks after the production of the CRF model, thrombosis 
was induced in the rat carotid artery using FeCl3 to determine 
in vivo thrombus formation, as previously described.15 Briefly, 
a midline cervical incision was made. Then, the left common 
carotid artery (CCA) was carefully dissected and exposed. A 
Doppler probe (MP4 Needle Probe; Motor Instruments, Axmin-
ster, UK) was located above the midportion of the CCA. Data 
of blood flow obtained with the probe were analyzed using soft-
ware (Moor Instruments, Devon, UK). After the measurement 
of baseline blood flow for 4 min, a 700 μm×500 μm filter paper 
saturated with 50% FeCl3 (F2877; Sigma-Aldrich Inc., St. Louis, 
MO, USA) was placed on the adventitia of the CCA for 5 min.15 
After removing the filter paper, the CCA was irrigated with 0.9% 
normal saline and blood flow was recorded. The time to initial 
thrombus formation was defined as decreased blood flow by 
10% of the baseline.15 The time to significant thrombus formation 
was defined as decreased blood flow by 50% of the baseline. To 
measure thrombus size, the CCA was fixed with 4% paraformal-
dehyde and embedded in paraffin for histopathological anal-
ysis. Paraffin blocks were consecutively cut into 3-μm sections. 
Sectioned slices were mounted on glass slides and stained with 
hematoxylin and eosin. Because the maximal diameter of a throm-
bus would be most likely to impact blood flow, the diameters of 
thrombi were measured using a light microscope (Axio Imager 
D2; Carl Zeiss Microimaging, Oberkochen, Germany) and Zeiss 
AxioVision software (AxioVs40 V 4.8.1.0, Carl Zeiss Imaging So-
lution) in a cross section that showed the largest diameter.15 
Urine, blood sampling, ROTEM, and IPA
During last the 24 hr before inducing thrombus formation, 24 
hr urine was acquired for measuring proteinuria and microal-
buminuria amounts. At 4 weeks after the initial surgery, blood 
was sampled through a cardiac puncture under general anes-
thesia immediately before sacrificing the rats. These blood 
samples were used to measure the levels of blood urea nitrogen 
(BUN), creatinine, fibrinogen, and antithrombin III. ROTEM 
and IPA were performed 60 min after blood sampling.19 
Blood samples for ROTEM were kept at room temperature, 
and all ROTEM analyses were performed at 37°C. ROTEM was 
carried out using 2.7 mL of whole blood that was gently mixed 
with 0.3 mL of 3.2% sodium citrate and reversed with 0.2 M of 
CaCl2 according to the manufacturer’s manual (ROTEM; Tem 
International GmbH, Munich, Germany).19,20 Aliquots of 340 μL 
of blood samples were used for extrinsic pathway screening 
thromboelastometry (EXTEM) and intrinsic pathway screen-
ing thromboelastometry (INTEM). Blood clot formation was 
evaluated with recombinant tissue factor for EXTEM and with 
contact activation for INTEM. The obtained parameters were 
time to clot initiation, time to clot formation, α angle for clot 
growth kinetics (initial rate of fibrin polymerization), and the 
maximum amplitude representing the viscoelastic strength of 
clot at 10 min and 20 min (MA10 and MA20, respectively) (Fig. 1).20
The degree of platelet aggregation was assessed by IPA (Chro-
nolog 700; Chronolog Co., Havertown, PA, USA).15 Briefly, car-
diac puncture was conducted to draw whole blood (900 μL) into 
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a syringe containing 100 μL of 150 United States Pharmacopeia 
(USP) sodium heparin solution, resulting in a final heparin 
concentration of 15 USP/mL. A total volume of 500 μL of hepa-
rinized whole blood was mixed with the same volume of nor-
mal saline. Adenosine diphosphate (ADP) (20 μM) was used as 
an agonist.
Statistical analysis
Statistical analyses were performed using SPSS (version 20.0; 
IBM Corp., Armonk, NY, USA). The independent t-test or Mann-
Whitney U-test were performed to compare the 24 hr protein-
uria, 24 hr microalbuminuria, BUN, creatinine, fibrinogen and 
antithrombin III, ROTEM parameters, IPA, and maximal throm-
bus diameter between the control group and the CRF group. A 
two-tailed p-value of <0.05 was considered statistically significant. 
For sample size estimation in ROTEM, previous study showed 
that the standard deviation of time to clot initiation and α angle 
was 5 in 43 normal Sprague-Dawley rats. Therefore, assuming 
an alpha error of 0.05, a beta error of 0.2, and a difference in 
mean values of more than 10, in order to prove that there was a 
difference in time to clot initiation or α angle between the con-
trol group and the CRF group, each group required five rats.21 
Regarding platelet aggregation, a previous study performed with 
three rats discovered a significant difference between ADP-
treated group and non-ADP-treated group.22 To minimize the 
number of animals required for experimentation, we assigned 
five rats as controls and five rats to the CRF group.
RESULTS
Mortality rates within 4 weeks were 21.0% (4 of 19) for the CRF 
model and 6.3% (1 of 16) for the control group. All five rats died 
within 48 h after the initial surgical procedures. The mortality 
of our CRF model was similar to that of a previous study.17 The 
30 rats that survived until 4 weeks were used for analyses [con-
trol: n=15 (5 for FeCl3-induced arterial thrombosis model, 5 
for ROTEM, and 5 for IPA), CRF: n=15 (5 for FeCl3-induced ar-
terial thrombosis model, 5 for ROTEM, and 5 for IPA)].
Urine and serum biochemistry
The CRF group had higher levels of 24 hr urine protein (124.4± 
33.0 mg vs. 13.3±1.2 mg, p=0.002), 24 hr urine microalbumin 
(5.4±1.5 mg vs. 0.2±0.1 mg, p=0.002), plasma BUN (57.0±18.9 
mg/dL vs. 17.8±3.7 mg/dL, p=0.021), creatinine (0.6±0.1 mg/
dL vs. 0.2±0.1 mg/dL, p=0.018), fibrinogen (299.8±18.5 mg/dL 
vs. 269.4±13.6 mg/dL, p=0.018), and lower levels of plasma anti-
thrombin III (93.8±2.2 vs. 110.2±5.8 international unit, p=0.036) 
than the control group. 
FeCl3-induced thrombus formation in vivo, ROTEM, 
and IPA
In experiments of FeCl3-induced thrombosis of the carotid ar-
tery, the time to mean blood flow reduction (10% and 50%) by 
thrombotic occlusion was shorter in the CRF group than in 
the control group (10%: 30.2±1.2 s vs. 42.1±1.4 s, p=0.001; 50%: 
114.6±15.2 s vs. 152.6±21.5 s, p=0.014) (Supplementary Fig. 1, 
only online). The maximal diameters of thrombi were larger 
in the CRF group than in the control group (394.2±201.1 μm vs. 
114.0±145.1 μm, p=0.039) (Fig. 2). 
In EXTEM, the CRF group showed a shorter time to clotting 
initiation (clotting time, 59.0±7.3 s vs. 72.8±5.0 s, p=0.032) and 
a higher velocity to clot growth (α angle, 84.8±0.2° vs. 82.0±0.6°, 
p=0.008) than the control group. The clot formation time, MA10, 
and MA20, were not different between the two groups (Table 
1, Fig. 3). However, in INTEM, the clotting time, clot formation 
time, α angle, MA10, and MA20 were not different between 
the CRF and control groups (Table 1, Fig. 3). On IPA, the maxi-
mal platelet aggregation rate was higher in the CRF group 
than in the control group (58.2±0.2% vs. 44.6±1.2%, p=0.006); 
however, there was no difference in the time to maximal aggre-
gation (331.0±10.8 s vs. 309.6±9.9 s, p=0.248) (Supplementary 
Fig. 2, only online).
DISCUSSION
This study showed that the thrombotic responses to external 
stimuli differ between rats with CRF and those with normal kid-












Fig. 1. Method of rotational thromboelastometry. The obtained parame-
ters were time to clot initiation (CT), time to clot formation (CFT), α angle for 
clot growth kinetics (initial rate of fibrin polymerization), and maximum am-
plitude representing the viscoelastic strength of clot at 10 min (MA10) 
and 20 min (MA20). CT, the latency time from adding the start reagent to 
blood until the clot starts to form; CFT, duration measured from r time to 
the point where the amplitude of the tracing measures reached 20 mm; 
α angle, the angle of tangent between 2 and the curve while CFT is the 
time from CT until a clot firmness of 20 mm point has been reached.
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formation is more rapidly induced in rats with CRF than in those 
with normal kidney function using the FeCl3-induced throm-
bus model. Maximal thrombus diameter, maximal platelet ag-
gregation rate, and plasma fibrinogen levels were also higher 
in the CRF group. Plasma anti-thrombin III levels were lower 
in the CRF group.
Direct application of FeCl3 to the arterial adventitia has 
Table 1. Comparison of Rotational Thromboelastometry Results be-
tween the Control Group and the CRF Group
Control (n=5) CRF (n=5) p value
 EXTEM 
Clotting time (s) 72.8±5.0 59.0±7.3 0.032
Clot formation time (s) 29.0±2.3 25.6±0.6 0.246
α angle (°) 82.0±0.6 84.8±0.2 0.008
MA10 (mm) 75.8±1.5 76.8±0.9 0.690
MA20 (mm) 78.2±1.1 80.4±0.6 0.222
 INTEM 
Clotting time (s) 81.6±5.9 83.6±4.8 1.000
Clot formation time (s) 26.0±0.7 24.2±0.5 0.151
α angle (°) 84.0±0.6 84.6±0.4 0.548
MA10 (mm) 73.8±0.8 75.6±0.8 0.310
MA20 (mm) 77.4±0.8 79.2±0.4 0.151
CRF, chronic renal failure; EXTEM, extrinsic pathway screening thromboelas-
tometry; INTEM, intrinsic pathway screening thromboelastometry; MA10, 
maximal amplitude at 10 min after the clotting time; MA20, maximal ampli-
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Fig. 3. Results of rotational thromboelastometry. (A) Extrinsic pathway screening thromboelastometry (EXTEM) for CRF rats. (B) EXTEM for control 
rats. (C) Intrinsic pathway screening thromboelastometry (INTEM) for CRF rats. (D) INTEM for control rats. In EXTEM, the CRF group (A) showed a 
shorter time to clotting initiation [clotting time (black arrow), 59.0±7.3 s vs. 72.8±5.0 s, p=0.032] and a higher velocity to clot growth (α angle, 84.8±0.2° 
vs. 82.0±0.6°, p=0.008) than the control group (B). The clot formation time, MA10, and MA20 were not different between the two groups. However, in 






Fig. 2. FeCl3-induced thrombus formation in the carotid artery. (A and B) 
Hematoxylin and eosin staining (×100). Thrombus is indicated with 
black arrow. CRF, chronic renal failure. (C and D) Gross findings. The 
maximal diameter of thrombus is larger in CRF than in control mice. Fe-
Cl3-induced thrombus formation site is indicated with white arrow.
Control CRF
been widely used for in vivo platelet-rich thrombus formation 
in animal models. This model has been shown to produce 
thrombi that have a similar morphology to those found in hu-
mans.23,24 FeCl3 induces clot formation by oxidative injury, en-
dothelial dysfunction, and endothelial collagen/glycoprotein 
VI axis activation.25 The endothelium is of crucial importance 
for hemostasis; however, it may lose its antithrombogenic 
properties, for example anti-thrombin III, in the presence of 
uremic toxic materials in CRF.26 Endothelial dysfunction and 
injury are aggravated in CRF.6,8 In the injured endothelium in 
CRF, endothelial release of tissue plasminogen activator is de-
creased, and thrombin is activated.8,26 This might enhance 
thrombus formation upon injury with FeCl3.
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ROTEM is a tool for assessing coagulation in humans and 
animals. This test determines the viscoelastic changes of co-
agulation, and reflects the clot initiation process, clot formation 
speed, and clot firmness.27 ROTEM has been proven superior 
to classical coagulation tests in evaluating potential coagula-
tion disorders.27 We determined whether enhanced thrombus 
formation on FeCl3-induced endothelial injury in CRF was me-
diated by the extrinsic or the intrinsic coagulation pathway. 
The findings in ROTEM suggest that enhanced clot formation 
in CRF was associated with the activation of the extrinsic co-
agulation pathway, which was triggered by tissue factor, but 
not of the intrinsic coagulation pathway. The tissue factor, which 
is the main initiator of the extrinsic coagulation pathway, is a 
key molecule in hemostasis and thrombus formation.28 The 
tissue factor could induce fibrin formation (associated with 
thrombin burst—α angle in ROTEM) and decrease the clot-
ting time (representing initial fibrin formation in ROTEM).28 
In a previous study, increased levels of plasma tissue factor 
have been observed in patients with CRF.29 These findings sug-
gest that the enhanced thrombus formation in ROTEM might 
be associated with enhanced tissue factor pathway in CRF.30 
IPA, using specifically whole blood samples, is a classic tool 
for evaluating platelet aggregation. This test has several ad-
vantages over conventional methods for investigating platelet 
aggregation because whole blood samples require less pro-
cessing time. Moreover, IPA replicates in vivo conditions be-
cause whole blood includes white and red blood cells, which 
affect platelet aggregation.31 We also tested the aggregation of 
platelets in CRF using platelet aggregometry. In the early stage 
of CRF, increased platelet aggregation and von Willebrand 
factor activity were associated with thrombotic tendency.8 In 
addition, reduced plasma levels of nitric oxide and L-arginine 
in CRF were related to increased platelet aggregation, which 
may enhance thrombosis.32,33 Our findings of increased plate-
let aggregation in CRF support those of previous studies and 
provide additional information on platelet aggregation in CRF.
Our study has several limitations. First, we investigated al-
terations in hemostasis and coagulation at 4 weeks after in-
ducing CRF in the rat. Although histopathologic findings of 
CRF was demonstrated after 2 weeks after 5/6 nephrectomy 
in the remnant kidneys of mice,16 a longer period after induc-
ing 5/6 ablation/infarction might have been necessary to re-
flect the pathophysiology of “chronic” renal failure. In addi-
tion, hemostasis and coagulation in CRF may be different 
according to the stage of CRF. While our study showed that 
relatively early-stage CRF (4 weeks), comparable to that of a 
previous CRF rat model,18,34 long-standing CRF may increase the 
risk of bleeding rather than thrombosis because of functional 
defect in the interaction of von Willebrand factor with glyco-
protein IIb–IIIa, acquired defect of cyclooxygenase activity, and a 
reduced ability to synthesize thromboxane A2.35,36 Therefore, 
the interpretation of our findings should be limited to the 4 
weeks after inducing CRF in the rat. Second, the sample size 
of this study was very small. Therefore, further studies are nec-
essary in larger samples with the longer-period model, such 
as an 8-week or 12-week 5/6 ablation/infarction model. Third, 
the detailed molecular mechanism of thrombus formation was 
not evaluated. Therefore, further studies are needed to support 
and confirm our findings. Fourth, although weight of rats may 
be changed and differed between 5/6 groups and control groups 
during the 4 weeks, we did not adjust for the weight of rats. This 
limitation could cause another bias regarding results of our 
study. Finally, although the thrombogenicity could be influ-
enced by the surgery (5/6 nephrectomy) itself, our study did not 
evaluate hemostasis status after immediate post operation.
In conclusion, this study demonstrated that thrombosis caused 
by external stimuli-induced endothelial injury was enhanced 
in CRF rat model. An activated extrinsic coagulation pathway 
may play an important role in clot generation in the CRF rat 
model induced by 5/6 ablation/infarction.
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